Midatech Pharma (LON:MTPH Nasdaq:MTP) is to take its gold-plated nanoparticle technology forward into trials as a treatment for advanced liver cancer.
Chief executive Jim Phillips tells Proactive: ”This is the first time that we’ve been able to advance a targeted chemotherapy in a way that’s not been possible until now, so it’s very exciting for us.”
”It’s the first targeted chemotherapy that we have developed completely in-house and will be our first one, we hope into patients”, Phillips added.
Compound MTR104 has been selected to start a formal new drug-enabling programme during 2017, with human studies scheduled for 2018.
Story by ProactiveInvestors